SCHEMBL1225698

SCHEMBL1225698

O=C(/C=C/c1ccc(C(F)(F)F)cc1)c1ccc(Cl)cc1

nearest known ligand 0.75

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 8/20 0.75
CYP1A1 P04798 7/20 0.75
P4HB P07237 1/20 0.75
MAOB P27338 10/20 0.72
CXCL12 P48061 1/20 0.67
MAOA P21397 2/20 0.65
CYP1A2 P05177 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657470 1.00 CYP1B1 (0.75) CYP1B1CYP1A1P4HBMAOBCXCL12
SCHEMBL657469 1.00 CYP1B1 (0.75) CYP1B1CYP1A1P4HBMAOBCXCL12
SCHEMBL1225700 1.00 CYP1B1 (0.75) CYP1B1CYP1A1P4HBMAOBCXCL12
Bromide SCHEMBL11819636 0.98 CYP1B1 (0.73) CYP1B1CYP1A1P4HBMAOBCXCL12
Bromide SCHEMBL11817481 0.98 CYP1B1 (0.73) CYP1B1CYP1A1P4HBMAOBCXCL12
Hydrochloric Acid SCHEMBL11814001 0.98 CYP1B1 (0.73) CYP1B1CYP1A1P4HBMAOBCXCL12
Hydrochloric Acid SCHEMBL11814006 0.98 CYP1B1 (0.73) CYP1B1CYP1A1P4HBMAOBCXCL12
Bromide SCHEMBL11819641 0.98 CYP1B1 (0.73) CYP1B1CYP1A1P4HBMAOBCXCL12
Bromide SCHEMBL11817475 0.98 CYP1B1 (0.73) CYP1B1CYP1A1P4HBMAOBCXCL12
SCHEMBL11816722 0.92 CYP1A1 (0.87) CYP1B1CYP1A1P4HBMAOBCXCL12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230407-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-09-22 US claimed
US-20030216459-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2003-11-20 US claimed
EP-1355921-A2 MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF North Shore-Long Island Jewish Health System (US) 2003-10-29 EP claimed
US-6589997-B2 1-Phenylprop-2-en-1-one derivatives as wound healing, anticarcinogenic, antiarthritic, antitumor, antiproliferative, antiinflammatory or antimetastasis agents NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM 2003-07-08 US claimed
US-20030045559-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM 2003-03-06 US claimed
WO-2002002593-A2 MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) 2002-01-10 WO claimed
CN-116082317-A Selenium-containing coumarin derivative, preparation method thereof and application thereof in preparation of antitumor drugs 浙江工业大学 2023-05-09 CN disclosed
US-8193177-B2 Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases ANGION BIOMEDICA CORP. (US) 2012-06-05 US disclosed
US-20110230407-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-09-22 US disclosed
US-7879898-B1 treating a chronic obstructive pulmonary disease using modulators of HGF/SF activity; for example, 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one; emphysema ANGION BIOMEDICA CORP. (US) 2011-02-01 US disclosed
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES ANGION BIOMEDICA CORP. 2010-10-07 US disclosed
US-20050096372-A1 Small-molecule modulators of hepatocyte growth factor/scatter factor activities PILLARISETTI SIVARAM (US) 2005-05-05 US disclosed
US-6855728-B2 Small-molecule modulators of hepatocyte growth factor / scatter factor activities NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) 2005-02-15 US disclosed
US-20030216459-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2003-11-20 US disclosed
EP-1355921-A2 MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF North Shore-Long Island Jewish Health System (US) 2003-10-29 EP disclosed
WO-2002002593-A2 MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) 2002-01-10 WO disclosed
US-3931152-A ANTITUBERCULAR AMERICAN CYANAMID COMPANY (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230407-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA HGF, HGFAC, HDGF CYP1B1 4829/4885CYP1A1 4722/4885P4HB 3328/4885
US-20030045559-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities HGF, HDGF, MET CYP1B1 3602/4885CYP1A1 3342/4885P4HB 3381/4885
US-20030216459-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities HGF, HDGF, MET CYP1B1 3602/4885CYP1A1 3342/4885P4HB 3381/4885
US-20050096372-A1 Small-molecule modulators of hepatocyte growth factor/scatter factor activities HGF, HDGF, MET CYP1B1 3602/4885CYP1A1 3342/4885P4HB 3381/4885
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES HGF, HDGF, HGFAC CYP1B1 3966/4885CYP1A1 4326/4885P4HB 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.